Welcome to our dedicated page for ENDP news (Ticker: ENDP), a resource for investors and traders seeking the latest updates and insights on ENDP stock.
Endo International plc (OTC: ENDPQ) maintains this comprehensive news hub to keep stakeholders informed about developments in specialty pharmaceuticals. Our curated collection features official press releases and verified updates directly impacting the company's operations and therapeutic innovations.
Visitors will find timely information on clinical trial progress, including collagenase clostridium histolyticum (CCH) research for plantar fibromatosis, regulatory milestones, strategic partnerships, and financial restructuring updates. The resource prioritizes verified updates across Endo's core therapeutic areas: pain management, urology, endocrinology, and oncology.
This centralized news source enables efficient tracking of both scientific advancements and organizational developments. All content undergoes rigorous verification to ensure accuracy and relevance for investment research and industry analysis.
Bookmark this page for direct access to Endo's latest announcements. For additional corporate information, visit the official Endo International website.
Endo International plc (NASDAQ: ENDP) announced the publication of Phase 3 data for Qwo® (collagenase clostridium histolyticum-aaes) in Dermatologic Surgery, showcasing its effectiveness for treating moderate to severe cellulite in the buttocks of adult women. Conducted between February and September 2018, the studies involved 843 women and demonstrated statistically significant improvement over placebo. Qwo is the first FDA-approved injectable specifically for this condition, with over half of participants achieving meaningful results, affirming its market potential.
Endo International plc (NASDAQ: ENDP) announced a default judgment on liability against its subsidiaries in the case Staubus, et al. v. Purdue Pharma, L.P., pending since 2017 in Tennessee. The lawsuit claims violations of Tennessee’s Drug Dealer Liability Act related to opioid sales. The Tennessee Supreme Court had ruled that District Attorneys General lacked standing, but a recent court ruling allowed counties to participate. The default judgment was imposed due to alleged discovery issues, with damages to be determined later. Endo plans to challenge the ruling.
Endo International plc (NASDAQ: ENDP) has announced the pricing of a private offering of $1.295 billion in senior secured notes with a 6.125% interest rate due in 2029. This represents an upsized offering of $295 million above initial expectations. Proceeds will be utilized to refinance existing term loans. The notes will be secured by first priority liens on the same collateral backing Endo’s current senior secured credit facilities and first lien notes. The offering will only be available to qualified institutional buyers under specific exemptions.
Endo International plc (NASDAQ: ENDP) announced plans to offer senior secured notes through its subsidiaries Endo Luxembourg Finance Company I S.à r.l. and Endo U.S. Inc. The offering will be secured by first priority liens on existing collateral and will be used to refinance an existing term loan. The notes will only be offered to qualified institutional buyers under Rule 144A and to international investors in compliance with Regulation S. This press release does not constitute an offer to sell or solicit offers to buy any securities.
Endo International plc (NASDAQ: ENDP) announced the commencement of refinancing for its $3.3 billion senior secured term loan due 2024. This refinancing aims to obtain a new senior secured term loan while maintaining the same guarantees and collateral as the existing credit. The transactions are expected to extend the debt maturity profile without increasing total indebtedness, thereby enhancing financial flexibility. Completion is anticipated in Q1 2021, although the success is subject to market conditions.
Endo International plc (NASDAQ: ENDP) reported its Q4 and full-year 2020 results, achieving total revenues of $760 million, a 1% decrease from 2019. The company saw a remarkable turnaround with a reported income of $141 million in Q4 2020 versus a loss of $208 million in Q4 2019. Adjusted income from continuing operations was $176 million. Notably, the Sterile Injectables segment grew 16% to $332 million, while Generic Pharmaceuticals saw a 20% decline. Looking forward, Endo provided 2021 financial guidance amidst uncertainties due to COVID-19.
Endo International plc (NASDAQ: ENDP) will present at the J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference on March 1, 2021, at 9:15 a.m. ET. A live webcast and audio archive will be accessible on their website. Attendees are advised to log in 10 minutes early to ensure proper setup. Endo focuses on providing quality therapies, leveraging a dedicated global workforce to enhance patient care and life quality.
Endo International plc (NASDAQ: ENDP) has appointed Jennifer M. Chao as a director, effective immediately, and she will also serve on the Audit and Compliance Committees. With over 25 years in biotech and life sciences, Ms. Chao enhances Endo's ten-member Board, adding her extensive finance and corporate strategy experience. Previously, she was Chairman of BioSpecifics Technologies and worked in investment research at leading banks. Her expertise is expected to strengthen Endo’s strategic priorities as the company advances its mission of delivering life-enhancing therapies.
Endo International plc (NASDAQ: ENDP) is set to announce its fourth-quarter and full-year 2020 financial results on February 25, 2021, after market close. A conference call and webcast will follow on February 26, 2021, at 7:30am ET. Interested participants can access the call via a U.S./Canada dial-in number (866) 497-0462 or International (678) 509-7598, with the passcode 8387347. A replay will be available until March 5, 2021. Endo is focused on delivering quality therapies to improve patients' lives.
On January 5, 2021, Endo International plc (NASDAQ: ENDP) announced a licensing agreement with Radius Health, Inc. (NASDAQ: RDUS) for the exclusive commercialization of abaloparatide in Canada, through its subsidiary Paladin Labs Inc. Abaloparatide is an investigational treatment for osteoporosis, with Paladin expected to file a New Drug Submission with Health Canada by Q1 2022. The drug is not yet approved in Canada, but Endo aims to address a significant treatment gap for osteoporosis patients.
